Filing Details

Accession Number:
0001209191-14-077687
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-12-23 14:54:43
Reporting Period:
2014-12-22
Filing Date:
2014-12-23
Accepted Time:
2014-12-23 14:54:43
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1273636 Applied Genetic Technologies Corp AGTC Biological Products, (No Disgnostic Substances) (2836) 593553710
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1472131 L Daniel Menichella C/O Applied Genetic Technologies Corp.
11801 Research Drive, Suite D
Alachua FL 32615
V.p. & Chief Business Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-12-22 9,000 $4.90 9,000 No 4 M Direct
Common Stock Disposition 2014-12-22 9,000 $20.83 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2014-12-22 9,000 $0.00 9,000 $4.90
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
117,968 2023-09-18 No 4 M Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.6535 to $21.01, inclusive. The reporting person undertakes to provide Applied Genetic Technologies Corporation, any security holder in Applied Genetic Technologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
  2. The option, representing a right to purchase a total of 126,968 shares, became exercisable for 25% of the underlying shares on September 18, 2014, and thereafer becomes exercisable for the remaining underlying shares in equal monthly installments over three years, resulting in the option becoming exercisable for 100% of the underlying shares on the fourth anniversary of the date of grant.